passing out on semaglutide GLP-1 drugs tied to elevated risk of low blood pressure episodes Ozempic: Users prioritize weight loss

doi: 10.4049/jimmunol.0901967

Clinical trials showed a possible average weight reduction of 20.9% among users

The FDA has received reports of adverse events associated with compounded semaglutide products, including dosing errors, contamination, and products containing incorrect ingredients

Zepbound, a brand name for tirzepatide, is a dual-agonist medication that activates both the GLP-1 and GIP pathways, while Wegovy, underpinned by the active ingredient semaglutide, operates as a single-agonist drug focusing only on the GLP-1 pathway

Curiously, the strongest anxiolytic effect came from the smallest administered dose of 0.5 mcg/kg body weight, whereas larger doses had smaller effects on anxiety [12]